KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs


Por: Volta-Durán, E, Alba-Castellon, L, Arena, LA, Sánchez, JM, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E and Unzueta, U

Publicada: 1 may 2026
Resumen:
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in celltargeted protein drugs.

Filiaciones:
Volta-Durán, E:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Placa Civ S-N, Barcelona 08193, Spain

 Univ Politecn Cataluna, Dept Opt & Optometria, BarcelonaTech UPC, C Violinista Vellsola 37, Terrassa 08222, Barcelona, Spain

 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

Alba-Castellon, L:
 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

 Inst Recerca St Pau IR St Pau, St Quinti 77-79, Barcelona 08041, Spain

 Josep Carreras Leukaemia Res Inst IJC, Badalona 08916, Spain

Arena, LA:
 Inst Recerca St Pau IR St Pau, St Quinti 77-79, Barcelona 08041, Spain

 Josep Carreras Leukaemia Res Inst IJC, Badalona 08916, Spain

Sánchez, JM:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Placa Civ S-N, Barcelona 08193, Spain

 Univ Nacl Cordoba, Inst Invest Biol & Tecnol IIBYT, CONICET, ICTA,FCEFyN,UNC, Ave Velez Sarsfield 1611, Cordoba, Argentina

:
 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

 Inst Recerca St Pau IR St Pau, St Quinti 77-79, Barcelona 08041, Spain

 Josep Carreras Leukaemia Res Inst IJC, Badalona 08916, Spain

Mangues, R:
 Inst Recerca St Pau IR St Pau, St Quinti 77-79, Barcelona 08041, Spain

Villaverde, A:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Placa Civ S-N, Barcelona 08193, Spain

 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

 Univ Autonoma Barcelona, Dept Genet & Microbiol, Placa Civ S-N, Barcelona 08193, Spain

Vázquez, E:
 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Placa Civ S-N, Barcelona 08193, Spain

 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

 Univ Autonoma Barcelona, Dept Genet & Microbiol, Placa Civ S-N, Barcelona 08193, Spain

Unzueta, U:
 CIBER Bioingn Biomat & Nanomed CIBER BBN, Barcelona 08193, Spain

 Inst Recerca St Pau IR St Pau, St Quinti 77-79, Barcelona 08041, Spain

 Josep Carreras Leukaemia Res Inst IJC, Badalona 08916, Spain

 Univ Autonoma Barcelona, Dept Genet & Microbiol, Placa Civ S-N, Barcelona 08193, Spain
ISSN: 09396411





European Journal of Pharmaceutics and Biopharmaceutics
Editorial
Elsevier BV, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 222 Número:
Páginas:
WOS Id: 001698915400001
ID de PubMed: 41690333
imagen Green Submitted, hybrid

MÉTRICAS